Recombinant Human GPA33/Glycop

Recombinant Human GPA33/Glycoprotein A33  (C474)

 

产品说明(Description)

Recombinant Human Glycoprotein A33 is produced by our Mammalian expression system and the target gene encoding Ile22-Val235 is expressed with a 6His tag at the C-terminus. 

Accession #: Q99795

Known as: Cell Surface A33 Antigen; Glycoprotein A33; GPA33

 

制剂（Formulation）

Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, 1mM EDTA, pH 7.4.

 

质量控制（Quality Control） 

 

Purity:            Greater than 95% as determined by reducing SDS-PAGE.    

Endotoxin:    Less than 0.1 ng/ug (1 EU/ug) as determined by LAL test.

 

复溶（Reconstitution）

Always centrifuge tubes before opening. Do not mix by vortex or pipetting.
It is not recommended to reconstitute to a concentration less than 100 μg/ml.
Dissolve the lyophilized protein in distilled water.
Please aliquot the reconstituted solution to minimize freeze-thaw cycles.    

 

保存（Storage）

Lyophilized protein should be stored at < -20°C, though stable at room temperature for 3 weeks.Reconstituted protein solution can be stored at 4-7°C for 2-7 days.Aliquots of reconstituted samples are stable at < -20°C for 3 months.     

 

背景（Background）

Human Glycoprotein A33 (GPA33) is a single-pass type I membrane protein, belongs to the CTX family of cell adhesion molecular within the immunoglobulin family, can be expressed in normal gastrointestinal epithelium and in 95% of colon cancers. GPA33 consists of one Ig-like C2-type domain and one Ig-like V-type domain. The predicted mature protein includes a single transmembrane domain, a extracellular region and a intracellular tail. Intracellular traffic and recycling to the cell surface appear to play an important role in GPA33 function and to have an influence on its surface density superseding translation regulation. GPA33 has become a promising target of immunologic therapy strategies. GPA33 may also play a important role in cell-cell recognition and signaling.

 

电泳(SDS-PAGE)

 

参考文献(Reference)

MULTI-SPECIFIC ANTIBODIES WITH AFFINITY FOR HUMAN A33 ANTIGEN AND DOTA METAL COMPLEX AND USES THEREOF[J]. Sarah Cheal. et al. 2020.

A33 ANTIBODY COMPOSITIONS AND METHODS OF USING THE SAME IN RADIOIMMUNOTHERAPY[J]. WU Zhihao. et al. 2020.

Development of a tetravalent anti-GPA33/anti-CD3 bispecific antibody for colorectal cancers[J]. Zhihao Wu. et al. Molecular Cancer Therapeutics. 2018.

Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity 86Y-or 177Lu-DOTA-Bn binding scFv C825/GPA33 IgG bispecific immunoconjugates[J]. Cheal S M. et al. European journal of nuclear medicine and molecular imaging. 2015.

 

 

FOR RESEARCH USE ONLY